Monopar Therapeutics Inc. beat EPS estimates 100% of the time across 1 reported quarters (1 beats, 0 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-0.67 | — | — | Miss |
| Q12026 FY2026 | $-1.06 | $-0.46 | +56.6% | Beat |
| Q1 FY2026 | $-0.90 | — | — | Miss |
Back to MNPR overview · MNPR holders · MNPR KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.